Overview
Helicobacter pylori (H. pylori) is a spiral-shaped bacterium that colonizes the human stomach and upper gastrointestinal tract. Over time, it damages the protective mucosal lining of the stomach, which normally shields the gastric epithelium from corrosive gastric acid. This damage allows acid to injure the stomach and duodenal lining, leading to gastritis, peptic ulcers, bleeding, and infections.
Helicobacter pylori infection is one of the most common chronic bacterial infections worldwide and is strongly associated with gastric ulcers, duodenal ulcers, and chronic gastritis. Serological testing for H. pylori antibodies (IgG, IgM, and IgA) detects the host immune response to infection rather than the organism itself.
Disease Process
As illustrated in the disease pathway diagram in the presentation (page 3), Helicobacter pylori organisms attack the gastric mucosa, increasing hydrochloric acid (HCl) secretion and disrupting mucosal defenses. This process results in gastritis and duodenitis, which can progress to gastric or duodenal ulcers.
As mucosal injury worsens, clinical symptoms begin to appear. Chronic infection may persist for years if untreated, leading to recurrent ulcer disease and complications.
Symptoms
Patients infected with Helicobacter pylori may be asymptomatic or present with a range of gastrointestinal complaints. Common symptoms include:
- Dull, burning pain in the stomach, often worse when the stomach is empty
- Excessive burping and bloating
- Abdominal pain and vomiting
- Blood in vomit or stool, indicating gastrointestinal bleeding
- Loss of appetite
- Unexplained weight loss
These symptoms are consistent with gastritis and peptic ulcer disease, as highlighted on page 4 of the presentation.
Antibody Types and Clinical Significance
H. pylori serology measures three antibody classes, each with different clinical implications:
- IgG Antibody (page 5):
IgG antibodies appear approximately 2 weeks after infection and may persist for years, even after successful eradication. A positive IgG result, therefore, does not confirm active infection and may reflect past exposure. Use of IgG alone can lead to unnecessary treatment. - IgM Antibody (page 6):
IgM antibodies appear around the 3rd week of infection and usually disappear by the 8th week. However, IgM testing has limited clinical value because most H. pylori–related disease is due to chronic infection, and IgM is often absent. - IgA Antibody (page 7):
IgA antibodies appear between the 3rd and 4th week and tend to fall after successful treatment, sometimes persisting up to 12 weeks. IgA may indicate a mucosal immune response, but it does not consistently correlate with stool antigen testing, limiting its standalone diagnostic utility.
Current studies (page 8) suggest that IgG, IgM, and IgA should be interpreted together for associated diagnosis rather than relying on a single antibody marker.
Risk Factors
Risk factors for Helicobacter pylori infection include poor sanitation, overcrowded living conditions, contaminated food or water, and close household contact. Chronic infection increases the risk of recurrent peptic ulcers, gastrointestinal bleeding, and long-term gastric inflammation.
Assay Methods
As outlined on page 9, laboratory methods for detecting H. pylori antibodies include:
- ELISA
- Immunoblotting
- Rapid diagnostic tests
These methods detect circulating antibodies in serum rather than active bacterial colonization.
Sample Collection, Storage, and Interpretation
Blood sample collection requires 3.0 mL of blood in a plain red-capped tube (page 10). Serum should be separated as early as possible.
Sample stability:
- Room temperature: 7 days
- Refrigerated (2–8°C): 14 days
- Frozen: 14 days
During transport, samples must remain refrigerated and should not be frozen unnecessarily to avoid degradation (page 11).
Interpretation of results (page 12):
- Negative: < 0.9 units/mL
- Equivocal: 0.9–1.1 units/mL
- Positive: > 1.1 units/mL
Reported sensitivity is 80–85%, and specificity is 75 – 80%.
Limitations
As emphasized on page 16, Helicobacter pylori antibody testing has significant limitations:
- Results are investigational and not recommended as a standalone diagnostic test
- Cannot reliably distinguish current from past infection
- Not suitable for post-treatment eradication monitoring
- Requires confirmation by other diagnostic methods
